Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-Daily Extended-Release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases.
This study was initiated following reports that some US-marketed generic methylphenidate ER products had substantially higher reporting rates of therapeutic failure than did the referenced brands.
METHODS: Through methodology similar to that used by the US Food and Drug Administration to investigate the issue with the US-marketed generic, reporting rates were calculated from cases of therapeutic failure identified in the Canadian Vigilance Adverse Reaction Online database for a 1-year period beginning 8 months after each product launch. Corresponding population exposure was estimated from the number of tablets dispensed. An in-depth analysis of narratives of individual case safety reports (ICSRs) with the use of the generic product was conducted in duplicate by 2 physicians to assess causality and to characterize the potential safety risk and clinical pattern of therapeutic failure. Similar secondary analyses were conducted on the US-marketed products.
FINDINGS: Reporting rates of therapeutic failure with the use of methylphenidate ER-C (generic) and OROS methylphenidate (brand name) were 411.5 and 37.5 cases per 100,000 patient-years, respectively (reporting rate ratio, 10.99; 95% CI, 5.93-22.21). In-depth analysis of narratives of 230 ICSRs of therapeutic failure with the Canadian-marketed generic determined that all ICSRs were either probably (60 [26%]) or possibly (170 [74%]) causally related to methylphenidate ER-C. Clinical symptoms suggestive of overdos...
Source: Clinical Therapeutics - Category: Drugs & Pharmacology Authors: Park-Wyllie L, van Stralen J, Castillon G, Sherman SE, Almagor D Tags: Clin Ther Source Type: research
More News: ADHD | Canada Health | Concerta | Databases & Libraries | Drugs & Pharmacology | Food and Drug Administration (FDA) | Hyperactivity | Marketing | Methylphenidate | Overdose | Ritalin | Study | USA Health